After two major acquisitions, Biosynth is coming to CPHI North America ready to tell the industry about its enhanced capabilities and connect with new and existing customers.
Pepticom’s technology aims to ‘vastly reduce’ risk of failure in peptide drug candidates’ discovery and development, by utilizing artificial intelligence models.
AstraZeneca and Aptamer Group will collaborate to leverage Aptamer’s platform for targeted delivery of oligonucelotides to the kidney for therapeutic development.
Almac announced it has increased its supply of neo-antigen peptides for individualized cancer treatments with the addition of another stream of GMP manufacturing.
Akzo Nobel business unit Diosynth, which specialises in the
production of complex active biopharmaceutical ingredients for the
pharmaceutical sector, has won a contract to apply its new method
for manufacturing synthetic peptides...
Peptide drugs look like they may finally fulfil their promise,
after years of what has largely been disappointment, if figures
released in a new market research report prove accurate.
Solvay subsidiary Peptisyntha is boosting its capacity to make
peptides at its facilities in California, US, in anticipation of
increasing numbers of drugs in this class coming through to market.
